symptoms did not seem to interfere with their son's functioning when the task at hand was of interest to Allan. At the time of assessment, Allan denied experiencing any suicidal ideation or a history of suicide attempts, but he reported vague thoughts that life was no longer worth living. Neither he nor his parents were able to identify any recent stressors, but there was a long-standing history of bullying by peers regarding his obesity. The provisional diagnosis after initial psychiatric interview was adjustment disorder with depressed mood. Psychometric testing revealed Allan to have average to superior abilities but a large discrepancy between verbal and performance IQ. On the Children's Depression Inventory (CDI), Allan endorsed several depressive symptoms, including suicidal ideation, with a total raw score of 27. This prompted an immediate risk assessment by the urgent care psychiatrist who failed to identify the patient as being at risk. That psychiatrist's clinical impression was adjustment disorder with depressed mood, with the significant stressor being bullying at school.
In this case, a child with depressive symptoms but no suicidal ideation on clinical exam received a nondepression diagnosis from 2 independent psychiatrists. Conversely, assessment using the CDI rated this boy as very much above average for depressive symptoms and as experiencing suicidal ideation. This case suggests that the CDI may be an indicator of distress but not necessarily of depressive illness. It further supports the use of psychometric tools (in this case, the CDI) as adjuncts to clinical diagnosis. While such tools are valuable in assessment, they should not be considered a reliable substitute for the clinical interviewing process in determining diagnosis or suicidal risk.
Treatment With Risperidone and Occurrence of Blurred Vision: A Question of Higher Dosage
The more frequently encountered ophthalmologic adverse events of neuropsychiatric agents include thioridazine-induced retinopathy, tricyclic antidepressant-induced accommodation interference and glaucoma, and lithium carbonate-induced exophthalmos and papilloedema. Clozapine may produce blurred vision, but this side effect is usually time-limited (1). According to available evidence, episodes of transient visual disturbances appear during treatment with risperidone but disappear when medication with risperidone is reduced to a lower daily dosage (2,3).
Methods
We assessed clinical somatic state, using laboratory values, ophtalmoscopy, biomicroscopy, EEG, and brain magnetic resonance imaging (MRI). We assessed psychic profiles, using the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) and the Clinical Global Impressions (CGI). We assessed side effects, using the Simpson-Angus Rating Scale for Extrapyramidal Syndrome, the Barnes Akathisia Scale (BAS), and the Extrapyramidal Symptom Rating Scale (ESRS).
Case Report
In June 2002, because of psychotic symptoms, the patient (aged 36 years, single, with no children, and an economist) was hospitalized in our clinic with a discharge diagnosis of psychosis schizoaffectiva according to DSM-IV (4) . After admission to our clinic, we continued therapy with promazine 400 mg daily, along with alprazolam 0.75 mg daily, zolpidem 10 mg daily, and fluoxetine 20 mg daily, and we started therapy with risperidone 2 mg daily. At baseline visit (that is, the first day of therapy with risperidone), we performed the PANSS, CGI, Simpson-Angus Rating Scale for Extrapyramidal Syndrome, BAS, and ESRS. The patient's total PANSS score was 86, and the CGI score was markedly ill. The values of hematology, biochemistry, and urinalysis were in referent range. EEG was normal. Because of persisting positive symptoms, we increased the dosage of risperidone to 12 mg daily. Promazine was discontinued from therapy. The patient became fully remitted after 4 weeks and was discharged. After 6 weeks of risperidone therapy (4 weeks as an inpatient and 2 weeks as an outpatient), the patient reported blurred vision. To clarify the origin of blurred vision, we assessed clinical somatic state. The values of hematology, biochemistry, and urinalysis were in referent range. The results of the neuropsychological assessment excluded lesions caused by cranial trauma, diffuse brain damage, or lesions caused with slow progressive process. The patient's brain MRI was normal, and the biomicroscopy results revealed no abnormalities. Ophtalmoscopy showed no pigment mottling or disturbances in the macular regions. Subsequently, the dosage of risperidone was reduced to 4 mg daily, and 2 weeks later, the patient reported full recovery of vision without worsening her mental condition. The diagnostic procedure showed no organic cause of the blurred vision. Also, blurred vision was not related to concomitant therapy.
Conclusion
Blurred vision is a side effect associated with treatment with risperidone in higher dosages, which may disappear, without worsening of symptoms, after decreasing the daily dosage of risperidone. Further observation is necessary for more precise understanding of these conditions, which is essential for diagnosis and appropriate treatment. scant reports of neutropenia occurring later in treatment.
We describe a case of nonleukopenic neutropenia 3 years after initiation of clozapine.
Mr D is aged 34 years and suffers from paranoid schizophrenia, first diagnosed in April 1992. Since 1994, he had been managed on a combination of haloperidol decanoate, carbamazepine, and fluoxetine. Several full blood pictures (FBPs) performed were within normal ranges.
Because of ongoing delusional thinking and the appearance of mild dyskinetic movements, clozapine was initiated in June 1998.
The patient's medical history comprised a grand mal epileptic seizure after a head injury in 1986. He had been seizure free since 1995.
Prior to starting clozapine, carbamazepine was replaced by sodium valproate. Baseline FBP showed a hemoglobin level of 160 g/L, a platelet count of 146´10 9 /L, a white cell count (WCC) of 6.7´10 9 /L with a neutrophil differential of 3.48´10 9 /L, lymphocytes 2.55´10 9 /L, monocytes of 0.4´10 9 /L, eosinophils of 0.2´10 9 /L, and basophils of 0.07´10 9 /L. Following initiation of clozapine, medications included clozapine 300 mg daily, sodium valproate 1g in the morning, and 1.5 g at night, sertraline 50 mg daily. There was a significant clinical response. In December 1999, monthly FBP revealed mild neutropenia (1.86´10 9 /L), with both a normal WCC (4.53´10 9 /L) and other white cell indices. The neutrophil count increased to 2.22´10 9 /L 2 days later and remained above 2´10 9 /L. There were 3 further episodes when Mr D's neutrophil count dropped below 2´10 9 /L with normal WCCs and other FBP parameters, all of which resolved spontaneously.
In July 2001, his clozapine dosage was reduced to 250 mg daily following a further transient drop in his neutrophil count. Morning and afternoon testing yielded similarly low levels of neutrophils, excluding morning neutropenia. In August 2001, the neutrophil count dropped to 1.42´10 9 /L (with normal indices hemoglobin 156 g/L, platelets 153´10 9 /L, WCC 5.84´10 9 /L, lymphocytes 3.59´10 9 /L, eosinophils 0.10´10 9 /L). Two days later, when the neutrophil count remained below 1.5´10 9 /L, clozapine was ceased.
Urea and electrolytes, liver function test, erythrocyte sedimentation rate (ESR), and C-reactive protein level were found to be normal. Physical examination for each episode of neutropenia was normal. Clozapine blood levels before stopping clozapine were 916 mcg/l; norclozapine levels were 214 mcg/l. Following discontinuation of clozapine, the neutrophil count remained between 1.51 0 9 /L and 2´10 9 /L for 3 weeks before increasing by the fifth week to 2.73´10 9 /L. At this time, Mr D began to show signs of relapse of his paranoid schizophrenia and was commenced on risperidone. Eight weeks following discontinuation, the neutrophil count was 2.93´10 9 /L.
This case is uncharacteristic of the usual picture of clozapine-associated neutropenia, which occurs much earlier after clozapine initiation, has a more rapid recovery time, and has been associated with eosinophilia or elevations in the WCC that might predate the neutropenia.
The primary etiological role of clozapine appears likely given the gradual resolution of the neutropenia upon cessation of clozapine. Further, there was no discernible evidence for a physical cause of the neutropenia.
The role of concomitant medication, especially valproic acid, remains unclear. This case confirms the necessity for ongoing hematological vigilance in patients taking clozapine.
